Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia
A legfontosabb adatok
- Ki végzi
- University Hospital, Strasbourg, France
- Hol
- Strasbourg (Franciaország)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 50 fő, tervezett
- Kezdés
- 2026. jún.
- Várható befejezés
- 2028. jún.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Analysis of GLP-1 receptor expression
- A regiszteradat frissítve
- 2026. január 14.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with peripheral artery disease (narrowed leg arteries) who have symptoms. It looks at a receptor called GLP1R on blood cells. People give one extra blood sample.
- Életkor
- 40 years or older
- Nem
- All sexes
- A betegség stádiuma
- Either leg pain when walking (intermittent claudication) with an Ankle-Brachial Index (ABI) < 0.9 at rest, or chronic limb-threatening ischemia: pain at rest and/or ulcers or gangrene for at least 15 days, with toe pressure or tcPO2 < 30 mmHg.
- Korábbi kezelés
- People currently taking SGLT2 inhibitors or GLP-1 receptor agonists cannot join.
A részvétel fő kizáró okai
- Type 1 or Type 2 diabetes
- Sepsis or an active infection spread through the body
- Active cancer or blood cancer
- Organ transplant, or autoimmune disease needing drugs that weaken the immune system; known chronic inflammatory diseases
- End-stage kidney disease needing dialysis
A regiszter feltételei, szó szerint
Mind a 9 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged 40 years or older
- Documented Peripheral Artery Disease (PAD): Patients must fall into one of the two following severity groups:; Intermittent Claudication (IC) Group: Defined by a maximum walking distance limited by intermittent claudication, associated with an Ankle-Brachial Index (ABI) < 0.9 at rest; Chronic Limb-Threatening Ischemia (CLTI) Group: Defined by ischemic rest pain and/or tissue loss (ulcers or gangrene) persisting for at least 15 days, associated with a toe pressure or a transcutaneous oxygen tension (tcPO2) < 30 mmHg, according to the 2024 ESC guidelines
Ki nem vehet részt
- Current Specific Pharmacotherapy: Ongoing treatment with SGLT2 inhibitors (SGLT2i) or GLP-1 receptor agonists (GLP-1RA)
- Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes
- Infection: Presence of sepsis or an active systemic infection
- Malignancy: Active cancer or hematologic malignancies
- Immunosuppression: History of organ transplantation or autoimmune diseases currently requiring immunosuppressive therapy
- Known chronic inflammatory diseases
- Advanced Renal Failure: End-stage renal disease requiring dialysis
Helyszínek itt: Franciaország
- Hopitaux Universitaires de StrasbourgStrasbourg, FranciaországContact: Elena-Mihaela CORDEANU, MCU-PHToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this observational study is to learn whether activation of the GLP-1 receptor could represent a therapeutic target by characterizing its expression and associated inflammatory mechanisms in patients with peripheral artery disease, according to disease severity, in adults with symptomatic lower-limb peripheral arterial disease.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Is the level of GLP-1 receptor (GLP1R) expression on peripheral blood mononuclear cells (PBMC) different between patients with intermittent claudication (ischemia of effort) and those with chronic limb-threatening ischemia? * Is GLP1R expression associated with inflammatory and oxidative profiles of PBMC? * Can GLP-1 receptor agonists reverse inflammatory and oxidative alterations induced by plasma from patients with peripheral artery disease in endothelial cell cultures? * Are there specific plasma proteomic signatures associated with GLP1R overexpression?
Researchers will compare patients with intermittent claudication to patients with chronic limb-threatening ischemia to see if disease severity is associated with differences in GLP1R expression, PBMC inflammatory/oxidative phenotype, and plasma proteomic profiles.
Participants will:
* Provide an additional blood sample (15 mL) collected during a routine, clinically indicated blood draw * Have PBMC isolated for measurement of GLP1R expression and assessment of inflammatory and oxidative markers * Have plasma analyzed for proteomic profiling and used in in-vitro endothelial cell experiments
Participation ends after completion of the blood sampling, and no additional procedures beyond standard clinical care are required.
A vizsgálat 2 csoportja
- Chronic Limb-Threatening Ischemia (CLTI)
A group of patients presenting with chronic limb-threatening ischemia, the most severe form of peripheral artery disease
Kezelés: Analysis of GLP-1 receptor expression
- Intermittent claudication (IC)
A group of patients presenting with intermittent claudication, a less advanced stage of of peripheral artery disease, serving as a comparator
Kezelés: Analysis of GLP-1 receptor expression
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. január 14.